Biodefense Breaking News: Aethlon Medical (OTCBB:
AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola
in the United States
SAN DIEGO - November 26, 2014 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic
devices to address infectious disease and cancer, today announced the first
shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus
infections in the United States. The Aethlon Hemopurifier® is a first-in-class
bio-filtration device that targets the rapid elimination of viruses and
immunosuppressive proteins from the circulatory system of infected individuals.
Aethlon
disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit
at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be
stockpiled for Ebola patients that may be treated at the NMC. Aethlon further
disclosed that it has provided onsite training to NMC clinical personnel
related to the implementation of Hemopurifier® therapy within the dialysis
infrastructure already located at the center.
The Nebraska Biocontainment Unit was
commissioned by The United States Centers for Disease Control (CDC) in 2005. It
is a joint project involving Nebraska Medicine, Nebraska Health and Human
Services, and the University of Nebraska Medical Center. It was designed to
provide the first line of treatment for people affected by bioterrorism or
extremely infectious naturally occurring diseases such as Ebola. It's the
largest facility of its kind in the U.S. The NMC has treated three Ebola
patients since the current outbreak. Additional details can be found online at: www.nebraskamed.com/biocontainment-unit
Aethlon previously reported the successful
administration of Hemopurifier® therapy to a Ugandan doctor who was infected
with Ebola virus and treated at the Frankfurt University Hospital in Germany.
At the time Hemopurifier® therapy was administered, the doctor was unconscious
and suffered from multiple organ failure. His viral load prior to the
administration of a single 6.5-hour Hemopurifier® treatment was measured at
400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral
load was measured at 1,000 copies/ml and never again rose above that level.
Viral load became undetectable five days after therapy. The treatment was well
tolerated with no adverse events reported.
Additionally,
a post-treatment elution protocol verified that 242 million Ebola viruses were
captured within the Hemopurifier® during treatment. The doctor has since made a
full recovery and has returned home to his family in Uganda.
In the United States, Hemopurifier® therapy
is available to treat Ebola patients through FDA expanded access
"emergency use" provisions to address life threatening circumstances
for which an alternative therapy is not available. At present, no antiviral therapy
or vaccine has proven to be effective against Ebola virus infection in humans.
Aethlon disclosed that it provided Hemopurifiers to the NMC on a humanitarian
basis and therefore will not generate revenues as a result of its initial
shipment.
Aethlon will soon begin the first U.S.
clinical Hemopurifier® studies following the United States Food and Drug
Administration's (FDA)'s approval of an Investigational Device Exemption (IDE).
The study will contribute safety data to advance the device as a broad-spectrum
countermeasure against bioterror and pandemic threats, including Ebola and
chronic viral pathogens such as HIV and Hepatitis C (HCV).
Read this release
in full at http://www.investorideas.com/CO/AEMD/news/2014/11261.asp
About Aethlon Medical, Inc.
Aethlon
Medical creates targeted therapeutic devices to address infectious disease,
cancer and neurodegenerative disorders. The company's lead product is the
Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device
that selectively targets the broad-spectrum elimination of circulating viruses
and tumor-secreted exosomes that promote cancer progression. Exosome Sciences,
Inc. is a majority owned subsidiary that is advancing exosome-based products to
diagnose and monitor cancer, infectious disease and neurological disorders. For
more information, please visit http://www.aethlonmedical.com and connect with
the Company on Twitter, LinkedIn,
Facebook and Google+.
Certain statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc. to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to
commercialize its future products, that the FDA will not approve the initiation
of the Company's clinical programs or provide market clearance of the company's
products, future human studies whether revenue or non-revenue generating of the
Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C therapies
or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense
against viral pathogens, including ebola, the Company's ability to raise
capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either
internally or through outside companies and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, the ability of the Company to meet the milestones contemplated in
the DARPA contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright laws
other than syndication rights. Investorideas is a news source on Google news
and Linkedintoday plus hundreds of syndication partners. Our site does not make
recommendations for purchases or sale of stocks or products. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
